Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Purpose
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Conditions
- Lung Adenocarcinoma
- Lung Non-Small Cell Carcinoma
- Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participants must be assigned to S1900E. Assignment to S1900E is determined by the LUNGMAP protocol genomic profiling using the FoundationOne assay. Biomarker eligibility for S1900E is based on the identification of a KRAS^G12C mutation - Participants must have confirmed stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC). Mixed histology NSCLC with less than 50% squamous component is allowed - Participants must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI). The CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality. Measurable disease must be assessed within 28 days prior to sub-study registration. Pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease. Non-measurable disease must be assessed within 42 days prior to sub-study registration. Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration - Participants must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study registration - Participants with known human immunodeficiency virus (HIV) infection must be receiving anti-retroviral therapy and have an undetectable viral load at their most recent viral load test within 6 months prior to sub-study registration - Participants with EGFR sensitizing mutations, EGFR T790M mutation, ALK gene fusion, ROS1 gene rearrangement, or BRAF V600E mutation must have progressed following all standard of care targeted therapy - Participants with spinal cord compression or brain metastases must have received local treatment to these metastases and remained clinically controlled and asymptomatic for at least 7 days following stereotactic radiation and/or 14 days following whole brain radiation, and prior to sub-study registration - Participants must have received at least one line of systemic treatment for stage IV or recurrent NSCLC - Participants must have progressed (in the opinion of the treating physician) following the most recent line of systemic therapy for NSCLC - Participants must have recovered (=< grade 1) from side effects of prior therapy. The exception is if a side effect from a prior treatment is known to be permanent without expected further recovery or resolution (i.e., endocrinopathy from immunotherapy or cisplatin neurotoxicity) - Participants must be able to swallow tablets whole - Pre-study history and physical exam must be obtained within 28 days prior to sub-study registration - Absolute neutrophil count (ANC) >= 1,500/uL obtained within 28 days prior to sub-study registration - Platelet count >= 75,000/uL obtained within 28 days prior to sub-study registration - Hemoglobin >= 9 g/dL obtained within 28 days prior to sub-study registration - Serum bilirubin =< institutional upper limit of normal (IULN) within 28 days prior to sub-study registration - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to sub-study registration. For participants with liver metastases, and ALT and AST must be =< 5 x IULN - Participants must have a serum creatinine =< 1.5 x IULN or calculated creatinine clearance >= 50 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to sub-study registration - Participants must have Zubrod performance status 0-1 documented within 28 days prior to sub-study registration - Participants of reproductive potential must have a negative serum pregnancy test within 28 days prior to sub-study registration - Participants must agree to have blood specimens submitted for circulating tumor DNA (ctDNA) - Participants must be offered the opportunity to participate in specimen banking and in correlative studies for collection and future use of specimens. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System - Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines - NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system - As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system - Participants with impaired decision-making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study (e.g., tracking pill consumption and reporting adverse events to the investigator). For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Exclusion Criteria
- Participants with spinal cord compression or brain metastases must not have residual neurological dysfunction, unless no further recovery is expected, and the participant has been stable on weaning doses of corticosteroids prior to sub-study registration - Participants must not have leptomeningeal disease unless: (1) asymptomatic and (2) only detected on radiographic imaging (i.e., not present in cytology from cerebral spinal fluid [CSF] if CSF sampled) - Participants must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to sub-study registration - Participants must not have received any radiation therapy within 14 days prior to sub-study registration, with the exception of stereotactic radiation to CNS metastases which must have been completed at least 7 days prior to sub-study registration - Participants must not have received prior AMG 510 or other KRAS^G12C specific inhibitor - Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study - Participants must not have had a major surgery within 14 days prior to sub-study registration. Participant must have fully recovered from the effects of prior surgery in the opinion of the treating investigator - Participants must not have any grade III/IV cardiac disease as defined by the New York Heart Association criteria (i.e., participants with cardiac disease resulting in marked limitation of physical activity or resulting in inability to carry on any physical activity without discomfort), unstable angina pectoris, and myocardial infarction within 6 months, or serious uncontrolled cardiac arrhythmia - Participants must not have a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen - Participants must not have gastrointestinal disorders that may impact drug absorption - Participants must not have received strong inducers of CYP3A4 (including herbal supplements such as St. John's wort) within 14 days prior to sub-study registration and must not be planning to use strong inducers of CYP3A4 throughout protocol treatment - Participants must not have received CYP3A4 sensitive substrates (with a narrow therapeutic window) within 14 days prior to sub-study registration and must not be planning to use CYP3A4 sensitive substrates (with a narrow therapeutic window) throughout protocol treatment - Participants must not be pregnant or nursing. Participants with uteri must have agreed to use an effective contraceptive method for at least one month after the last dose of AMG 510. Participants with sperm must have agreed to use an effective contraceptive method for at least 3 months after the last dose of AMG 510. Participants are considered to be of "reproductive potential" if they have had menses at any time in the preceding 12 consecutive months and no prior oophorectomy and/or hysterectomy. In addition to routine contraceptive methods, "effective contraception" for participants with uteri also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. Acceptable methods of birth control for participants with sperm include sexual abstinence (refraining from heterosexual intercourse); vasectomy with testing showing there is no sperm in the semen; bilateral tubal ligation or occlusion in the partner; or a condom (the female partner should also consider a form of birth control). However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Treatment (AMG 510) |
Patients receive AMG 510 PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Anchorage, Alaska 99508
Fairbanks, Alaska 99701
Jonesboro, Arkansas 72401
Anaheim, California 92806
Arroyo Grande, California 93420
Auburn, California 95602
Baldwin Park, California 91706
Bellflower, California 90706
Berkeley, California 94704
Duarte, California 91010
Fontana, California 92335
Fremont, California 94538
Fresno, California 93720
Harbor City, California 90710
Irvine, California 92618
La Jolla, California 92093
Los Angeles, California 90027
Los Angeles, California 90034
Los Angeles, California 90048
Site Public Contact
310-423-8965
Modesto, California 95355
Oakland, California 94611
Ontario, California 91761
Palo Alto, California 94301
Palo Alto, California 94304
Panorama City, California 91402
Riverside, California 92505
Roseville, California 95661
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95817
Site Public Contact
916-734-3089
San Diego, California 92120
San Francisco, California 94115
San Francisco, California 94115
San Francisco, California 94121
Site Public Contact
415-221-4810
San Jose, California 95119
San Leandro, California 94577
San Marcos, California 92078
San Rafael, California 94903
Santa Clara, California 95051
Santa Cruz, California 95065
South San Francisco, California 94080
Sunnyvale, California 94086
Torrance, California 90505
Truckee, California 96161
Site Public Contact
530-582-6450
Vallejo, California 94589
Vallejo, California 94589
Walnut Creek, California 94596
Woodland Hills, California 91367
Aurora, Colorado 80012
Boulder, Colorado 80304
Centennial, Colorado 80112
Denver, Colorado 80218
Denver, Colorado 80220
Englewood, Colorado 80113
Englewood, Colorado 80113
Greeley, Colorado 80631
Littleton, Colorado 80120
Lone Tree, Colorado 80124
Loveland, Colorado 80539
Hartford, Connecticut 06102
Site Public Contact
860-545-5363
Meriden, Connecticut 06451
Site Public Contact
866-662-5678
New Britain, Connecticut 06050
Site Public Contact
860-224-5660
West Haven, Connecticut 06516
Site Public Contact
203-937-3421
Dover, Delaware 19901
Frankford, Delaware 19945
Milford, Delaware 19963
Newark, Delaware 19713
Newark, Delaware 19713
Rehoboth Beach, Delaware 19971
Tampa, Florida 33612
Weston, Florida 33331
Decatur, Georgia 30033
Site Public Contact
404-321-6111
Gainesville, Georgia 30501
Savannah, Georgia 31405
Valdosta, Georgia 31602
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Site Public Contact
808-486-6000
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Site Public Contact
808-532-0315
Honolulu, Hawaii 96813
Site Public Contact
808-545-8548
Honolulu, Hawaii 96813
Site Public Contact
808-522-4333
Honolulu, Hawaii 96817
Site Public Contact
808-531-8521
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Nampa, Idaho 83686
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Danville, Illinois 61832
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Galesburg, Illinois 61401
Hines, Illinois 60141
Site Public Contact
708-202-8387
Kewanee, Illinois 61443
Macomb, Illinois 61455
Mattoon, Illinois 61938
O'Fallon, Illinois 62269
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Silvis, Illinois 61282
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Urbana, Illinois 61801
Washington, Illinois 61571
Fort Wayne, Indiana 46845
Site Public Contact
877-784-4673
Indianapolis, Indiana 46202
Indianapolis, Indiana 46237
Site Public Contact
317-528-7060
Michigan City, Indiana 46360
Mooresville, Indiana 46158
Site Public Contact
317-834-3603
Richmond, Indiana 47374
South Bend, Indiana 46601
Site Public Contact
800-284-7370
Terre Haute, Indiana 47804
Site Public Contact
812-238-7394
Ames, Iowa 50010
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Davenport, Iowa 52803
Davenport, Iowa 52804
Davenport, Iowa 52807
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Jefferson, Iowa 50129
Site Public Contact
515-956-4132
Hays, Kansas 67601
Site Public Contact
785-623-5774
Lawrence, Kansas 66044
Olathe, Kansas 66061
Pittsburg, Kansas 66762
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Lexington, Kentucky 40536
Site Public Contact
859-257-3379
Baton Rouge, Louisiana 70816
Baton Rouge, Louisiana 70836
Kenner, Louisiana 70065
New Orleans, Louisiana 70121
Bangor, Maine 04401
Site Public Contact
207-973-4274
Brewer, Maine 04412
Site Public Contact
800-987-3005
Beverly, Massachusetts 01915
Site Public Contact
978-922-3000
Burlington, Massachusetts 01805
Gloucester, Massachusetts 01930
Site Public Contact
978-283-4000
Peabody, Massachusetts 01960
Worcester, Massachusetts 01655
Ann Arbor, Michigan 48106
Battle Creek, Michigan 49017
Detroit, Michigan 48236
East China Township, Michigan 48054
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Grand Rapids, Michigan 49503
Grosse Pointe Woods, Michigan 48236
Grosse Pointe Woods, Michigan 48236
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Lansing, Michigan 48912
Livonia, Michigan 48154
Livonia, Michigan 48154
Macomb, Michigan 48044
Muskegon, Michigan 49444
Norton Shores, Michigan 49444
Reed City, Michigan 49677
Saginaw, Michigan 48601
Saginaw, Michigan 48604
Saint Joseph, Michigan 49085
Sterling Heights, Michigan 48312
Tawas City, Michigan 48764
Traverse City, Michigan 49684
Warren, Michigan 48088
Warren, Michigan 48093
Warren, Michigan 48093
West Branch, Michigan 48661
Wyoming, Michigan 49519
Bemidji, Minnesota 56601
Deer River, Minnesota 56636
Duluth, Minnesota 55805
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
Minneapolis, Minnesota 55417
Site Public Contact
612-467-2800
Robbinsdale, Minnesota 55422
Sandstone, Minnesota 55072
Virginia, Minnesota 55792
Columbus, Mississippi 39705
Grenada, Mississippi 38901
New Albany, Mississippi 38652
Oxford, Mississippi 38655
Southhaven, Mississippi 38671
Cape Girardeau, Missouri 63703
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Joplin, Missouri 64804
Kansas City, Missouri 64108
Site Public Contact
816-404-4375
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59804
Las Vegas, Nevada 89102
Las Vegas, Nevada 89148
Concord, New Hampshire 03301
Site Public Contact
603-224-2556
Lebanon, New Hampshire 03756
Manchester, New Hampshire 03103
Site Public Contact
800-339-6484
Moorestown, New Jersey 08057
Site Public Contact
856-247-7395
Voorhees, New Jersey 08043
Site Public Contact
856-247-7395
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87110
Rio Rancho, New Mexico 87124
Buffalo, New York 14263
Cooperstown, New York 13326
East Hills, New York 11548
Elmira, New York 14905
Site Public Contact
607-271-7000
Rochester, New York 14642
Site Public Contact
585-275-5830
West Islip, New York 11795
Site Public Contact
631-376-4444
Durham, North Carolina 27705
Bismarck, North Dakota 58501
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Belpre, Ohio 45714
Canton, Ohio 44710
Centerville, Ohio 45459
Centerville, Ohio 45459
Chillicothe, Ohio 45601
Cleveland, Ohio 44111
Cleveland, Ohio 44195
Columbus, Ohio 43213
Columbus, Ohio 43214
Columbus, Ohio 43214
Columbus, Ohio 43215
Columbus, Ohio 43219
Columbus, Ohio 43222
Columbus, Ohio 43228
Dayton, Ohio 45409
Dayton, Ohio 45415
Dayton, Ohio 45415
Delaware, Ohio 43015
Delaware, Ohio 43015
Findlay, Ohio 45840
Franklin, Ohio 45005
Kettering, Ohio 45409
Kettering, Ohio 45429
Lancaster, Ohio 43130
Mansfield, Ohio 44903
Mansfield, Ohio 44906
Marietta, Ohio 45750
Marion, Ohio 43302
Mayfield Heights, Ohio 44124
Mount Vernon, Ohio 43050
Newark, Ohio 43055
Portsmouth, Ohio 45662
Sandusky, Ohio 44870
Springfield, Ohio 45504
Strongsville, Ohio 44136
Sylvania, Ohio 43560
Site Public Contact
419-824-1842
Warrensville Heights, Ohio 44122
Westerville, Ohio 43081
Wooster, Ohio 44691
Zanesville, Ohio 43701
Lawton, Oklahoma 73505
Site Public Contact
877-231-4440
Oklahoma City, Oklahoma 73104
Clackamas, Oregon 97015
Newberg, Oregon 97132
Ontario, Oregon 97914
Portland, Oregon 97213
Portland, Oregon 97225
Portland, Oregon 97227
Portland, Oregon 97239
Allentown, Pennsylvania 18103
Bethlehem, Pennsylvania 18017
East Norriton, Pennsylvania 19401
Ephrata, Pennsylvania 17522
Site Public Contact
717-721-4840
Gettysburg, Pennsylvania 17325
Site Public Contact
877-441-7957
Hanover, Pennsylvania 17331
Site Public Contact
717-632-1559
Harrisburg, Pennsylvania 17109
Lebanon, Pennsylvania 17042
Philadelphia, Pennsylvania 19111
Site Public Contact
215-728-4790
Philadelphia, Pennsylvania 19140
Site Public Contact
215-728-2983
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pottstown, Pennsylvania 19464
Site Public Contact
610-327-7544
Williamsport, Pennsylvania 17701
Site Public Contact
800-598-4282
York, Pennsylvania 17403
Site Public Contact
877-441-7957
York, Pennsylvania 17403
Site Public Contact
877-441-7957
Anderson, South Carolina 29621
Boiling Springs, South Carolina 29316
Site Public Contact
864-241-6251
Charleston, South Carolina 29401
Easley, South Carolina 29640
Site Public Contact
864-241-6251
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29605
Site Public Contact
864-241-6251
Greenville, South Carolina 29615
Site Public Contact
864-241-6251
Greer, South Carolina 29650
Site Public Contact
864-241-6251
Seneca, South Carolina 29672
Site Public Contact
864-241-6251
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Collierville, Tennessee 38017
Memphis, Tennessee 38120
Amarillo, Texas 79106
Dallas, Texas 75235
Dallas, Texas 75390
Berlin, Vermont 05602
Site Public Contact
802-225-5400
Mechanicsville, Virginia 23116
Midlothian, Virginia 23114
Richmond, Virginia 23226
Richmond, Virginia 23230
Richmond, Virginia 23249
Bremerton, Washington 98310
Edmonds, Washington 98026
Issaquah, Washington 98029
Kennewick, Washington 99336
Longview, Washington 98632
Port Townsend, Washington 98368
Site Public Contact
360-344-3091
Seattle, Washington 98122-4307
Huntington, West Virginia 25701
Site Public Contact
304-399-6617
Huntington, West Virginia 25702
Site Public Contact
304-526-1349
Antigo, Wisconsin 54409
Ashland, Wisconsin 54806
Brookfield, Wisconsin 53045
Burlington, Wisconsin 53105
Franklin, Wisconsin 53132
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54311
Kenosha, Wisconsin 53142
La Crosse, Wisconsin 54601
Marinette, Wisconsin 54143
Medford, Wisconsin 54451
Mequon, Wisconsin 53097
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53211
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53233
Oconto Falls, Wisconsin 54154
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53405
Racine, Wisconsin 53406
Sheboygan, Wisconsin 53081
Sturgeon Bay, Wisconsin 54235-1495
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
Wauwatosa, Wisconsin 53226
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
More Details
- NCT ID
- NCT04625647
- Status
- Recruiting
- Sponsor
- SWOG Cancer Research Network
Detailed Description
PRIMARY OBJECTIVE: I. To evaluate the response rate (confirmed, complete or partial) of AMG 510 in participants with KRAS^G12C mutated stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC). SECONDARY OBJECTIVES: I. To evaluate investigator assessed progression-free survival (IA-PFS) within each cohort. II. To evaluate overall survival (OS) within each cohort. III. To evaluate duration of response (DOR) among responders within each cohort. IV. To evaluate the frequency and severity of toxicities within the full study population (all cohorts combined). TRANSLATIONAL MEDICINE OBJECTIVES: I. To evaluate the association between clinical outcomes (response, IA-PFS, OS) and other co-mutations (e.g., CDKN2A/B/C, ATM, PIK3CA) identified by the Foundation Medicine Inc (FMI) FoundationOne CDx from LUNGMAP, within cohorts and across the full study population of KRAS^G12C positive participants. II. To evaluate the association between clinical outcomes (response, IA-PFS, OS) and PD-L1 total proportion score determined by screening in LUNGMAP, within cohorts and across the full study population of KRAS^G12C positive participants. III. To evaluate the association between clinical outcomes (response, IA-PFS, OS) and Tumor Mutational Burden Score determined by the FMI FoundationOne CDx from LUNGMAP, within cohorts and across the full study population of KRAS^G12C positive participants. IV. To collect, process, and bank cell-free deoxyribonucleic acid (cfDNA) at pre-treatment on cycle 1 day 1, cycle 2 day 1, cycle 3 day 1, and at progression for future development of a proposal to evaluate comprehensive next-generation sequencing of circulating tumor DNA (ctDNA) and association with clinical outcomes. Note: The translational medicine proposal to use these specimens will be submitted as a revision to CTEP for approval, prior to the SWOG Statistical and Data Management Center (SDMC) review of assay results. OUTLINE: Patients receive AMG 510 orally (PO) once daily (QD) on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 3 years if the disease has not gotten worse at the time of finishing study treatment. If the disease has gotten worse, patients are followed up every 6 months for 2 years, then at the end of the 3 years from the time they go on study.